media – Page 712 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

Hanmi Pharma gives up on development of lung cancer drug Olita

South Korean pharmaceutical firm Hanmi Pharmaceutical is expected to cease development of Olita, a lung cancer treatment, following its slow progress in clinical trials and cancellation of licensing deals with foreign drug makers.
- Source: koreaher
- 2,528
- April 20, 2018
Clinical Trials Company Insights Olita
FDA’s 2019 budget request cites digital health; agency rolls out medical device initiative

Digital health appears to be making its way onto the national stage. On Tuesday, FDA Commissioner Scott Gottlieb gave the field a shout-out in his remarks to the US House Subcommittee on Agriculture, Rural Development concerning the Fiscal Year 2019 budget request for the FDA.
- Source: MobiHealthNews
- 839
- April 20, 2018
digital health FDA
After successful pilot, Boehringer Ingelheim, HealthPrize roll out digital adherence tool more broadly

Following a successful nine-month pilot, Boehringer Ingelheim and HealthPrize Technologies announced that the digital adherence support program RespiPoints will be expanded to any patient who is taking certain Boehringer Ingelheim medications, including some available in the Respimat inhaler.
- Source: MobiHealthNews
- 753
- April 20, 2018
Boehringer Ingelheim Company Insights digital health
Which features of healthcare apps do patients desire most?

A new survey from customer experience agency Verndale found consumers most strongly want healthcare apps to provide the ability to manage appointments. Other most desired features among all patients include providing an alert when an appointment is running late, the ability to refill prescriptions and access to medical records.
- Source: MedCityNews
- 971
- April 20, 2018
healthcare Market Views mHealth
Carpe Secures $2.3M Seed Funding

Carpe, a skincare startup offering over-the-counter relief for excessive hand and foot sweating to the estimated 365 million hyperhidrosis sufferers worldwide, announced today that it has raised $2.3 million in seed funding. The round was co-led by the Carolina Angel Network and Duke Angel Network, affiliated with the University of North Carolina and Duke University's alumni networks respectively. Other investors include LaunchCapital, Rubicon Venture Capital, and Triangle Angel Partners.
- Source: vcnewsdaily
- 978
- April 19, 2018
Hyperhidrosis Market Views Series
J&J buys into Bristol-Myers cardiovascular disease program

Johnson & Johnson has bought into Bristol-Myers Squibb’s Factor XIa inhibitor program. The deal gives J&J a stake in the development and potential commercialization of anticoagulants including phase 2-ready secondary stroke candidate BMS-986177.
- Source: Fiercebiotech
- 2,471
- April 19, 2018
anticoagulants inhibitor Market Views
Ultragenyx and Kyowa Kirin Announce FDA Approval of Crysvita® (burosumab-twza) for the Treatment of Children and Adults with X–Linked Hypophosphatemia (XLH)

First Approved Therapy for XLH in the U.S.; Only Treatment that Targets the Underlying Cause of this Rare, Hereditary, Lifelong Disease
- Source: globenewswire
- 1,254
- April 19, 2018
biopharmaceutical FDA New Approvals rare and ultra-rare diseases
Shire——FDA approves VONVENDI® for perioperative management of bleeding in adult patients with von Willebrand disease

Cambridge, Ma. -- Shire plc, the global biotechnology leader in rare disease, today announced the U.S. Food and Drug Administration (FDA) has approved VONVENDI [von Willebrand factor (recombinant)], a recombinant von Willebrand factor (rVWF) treatment for perioperative management of bleeding in adults (age 18 and older) with von Willebrand disease (VWD).
- Source: 4-traders;
- 921
- April 19, 2018
New Approvals rVWF VONVENDI VWD
FDA medical device plan zeros in on cybersecurity, public-private partnership

The agency released a five-point plan outlining regulatory changes to bolster medical device safety, including requiring manufacturers ensure devices can be updated and patched.
- Source: HealthcareIT News
- 883
- April 19, 2018
cybersecurity digital health FDA Policies
Artificial pancreas is a safe and effective treatment for type 1 diabetes

Use of an artificial pancreas is associated with better control of blood sugar levels for people with type 1 diabetes compared with standard treatment, finds a review of the available evidence published by The BMJ today.
- Source: MedicalXpress
- 781
- April 19, 2018
diabetes digital health Researches

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.